May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Variation Within Apolipoprotein E May Protect Against Age–Related Macular Degeneration Through Cytokine Regulation
Author Affiliations & Notes
  • C.M. Bojanowski
    George Washington School of Medicine, Washington, DC
    Laboratory of Immunology,
    National Eye Institute, Bethesda, MD
  • D. Shen
    Laboratory of Immunology,
    National Eye Institute, Bethesda, MD
  • R.J. Ross
    Laboratory of Immunology,
    National Eye Institute, Bethesda, MD
  • E.Y. Chew
    Division of Epidemiology and Clinical Research,
    National Eye Institute, Bethesda, MD
  • W.R. Green
    Wilmer Ophthalmological Institute, Johns Hopkins School of Medicine, Baltimore, MD
  • C.–C. Chan
    Laboratory of Immunology,
    National Eye Institute, Bethesda, MD
  • J. Tuo
    Laboratory of Immunology,
    National Eye Institute, Bethesda, MD
  • Footnotes
    Commercial Relationships  C.M. Bojanowski, None; D. Shen, None; R.J. Ross, None; E.Y. Chew, None; W.R. Green, None; C. Chan, None; J. Tuo, None.
  • Footnotes
    Support  NEI Intramural Research Program
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 4156. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.M. Bojanowski, D. Shen, R.J. Ross, E.Y. Chew, W.R. Green, C.–C. Chan, J. Tuo; Variation Within Apolipoprotein E May Protect Against Age–Related Macular Degeneration Through Cytokine Regulation . Invest. Ophthalmol. Vis. Sci. 2006;47(13):4156.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : CCL2 (a chemokine) and VEGF (a cytokine) have previously been associated with age–related macular degeneration (AMD). Early AMD is characterized by an accumulation of lipid–containing drusen within Bruch’s membrane. ApoE, a major polymorphic CNS apolipoprotein, is found in high levels in soft drusen as well as in eyes affected by neuroretinal damage. Variation within ApoE (at positions C112R and R158C) is associated with AMD. The aim of this study is to determine the possible mechanisms underlying this association by studying the effects of recombinant ApoE isoforms on the expression of CCL2 and VEGF in cultured retinal pigmented epithelium (RPE) cells.

Methods: : Genomic DNA was PCR amplified following extraction from peripheral blood collected from 299 age–matched controls with no clinical signs of AMD and 407 advanced AMD patients from the AREDS cohort. Genomic DNA was also collected, following microdissection and whole genome amplification, from 40 archived paraffin–embedded ocular slides of pathologically diagnosed AMD patients. ApoE Cys112Arg (rs#429358) and Arg158Cys (rs#7412) SNP typing was performed using both RFLP and Taqman allele discrimination assays. Functional studies conducted by co–incubation of RPE cells with the ApoE E3 and E4 isoforms were performed. Culture mediums were subjected to ELISA assays for CCL2 and VEGF analysis.

Results: : ApoE 112R distribution differed significantly between AMD patients and controls with allele frequencies of 5% (4/80) in the archived AMD cases, 10.7% (87/814) in AMD patients, and 14.6% (87/598) in the age–matched controls. Significant differences in ApoE 158C distribution were not observed. In vitro studies found that recombinant ApoE suppresses CCL2 and VEGF expression in RPE cells. However, the E4 isoform (112R/158R) showed greater suppression than E3 (112C/158R) in both cases.

Conclusions: : The results of our study further confirm the association between the ApoE 112R non–synonymous variant and a decreased risk of AMD development. In vitro studies suggest that one of the underlying mechanisms of this association may involve the differential regulation of both CCL2 and VEGF expression in RPE cells by the ApoE isoforms. This finding may help to identify targeted therapeutic strategies for the treatment of this debilitating disease.

Keywords: age-related macular degeneration • cytokines/chemokines • clinical (human) or epidemiologic studies: risk factor assessment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×